Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €56.50 EUR
Change Today -0.286 / -0.50%
Volume 1.9K
4AB On Other Exchanges
New York
EN Paris
As of 10:51 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (4AB) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/29/15 - €65.58
52 Week Low
10/23/15 - €42.44
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABBVIE INC (4AB)

abbvie inc (4AB) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.

28,000 Employees
Last Reported Date: 11/6/15
Founded in 2012

abbvie inc (4AB) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.6M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $923.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $1.5M
Executive Vice President of Commercial Operat...
Total Annual Compensation: $844.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $957.6K
Compensation as of Fiscal Year 2014.

abbvie inc (4AB) Key Developments

Abbvie Receives Health Canada Approval for TECHNIVIE for the Treatment of Adults with Genotype 4 Chronic Hepatitis C Infection

AbbVie announced that Health Canada granted a Notice of Compliance (NoC) to TECHNIVIE (ombitasvir/paritaprevir/ritonavir tablets) in combination with ribavirin (RBV) for the treatment of adults with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis who are either treatment naïve or previously treated with peginterferon and ribavirin. This approval of TECHNIVIE is based on data from the PEARL-I study, which demonstrated 100% sustained virologic response rates at 12 weeks post-treatment (SVR12) in patients who received TECHNIVIE and RBV for 12 weeks. PEARL-I is an open-label Phase 2b study that evaluated the efficacy and safety of TECHNIVIE in GT4 chronic HCV patients without cirrhosis. The study included GT4 patients who were new to therapy (n=42/42) or who had failed previous treatment with pegylated interferon (pegIFN) and RBV (n=49/49). Additionally, 91% of patients who were new to therapy achieved SVR12 (n=40/44) after taking TECHNIVIE without RBV. In the treatment-naïve group without RBV, on-treatment virologic failure was reported in one patient (2%), and two patients (5%) experienced post-treatment relapse. There were no virologic failures in the other treatment arms. Important Safety Information: TECHNIVIE (ombitasvir/paritaprevir/ritonavir tablets) is a prescription medicine used with ribavirin to treat adults with genotype 4 chronic (lasting a long time) hepatitis C (hep C) virus infection without cirrhosis. To help avoid side effects and make sure one is using the medicines correctly, talk to the doctor before one person take TECHNIVIE. Talk about any health problems one may have: are taking birth control medicines of any kind or using a medicine that has ethinyl estradiol. Ethinyl estradiol is usually found in birth control pills. However, not all birth control pills have ethinyl estradiol. One must not use medicines that have ethinyl estradiol while taking TECHNIVIE. Doctor will ask one to stop or change to a different type of birth control while one is taking TECHNIVIE; have had a liver transplant; have liver problems other than HCV infection; and are breastfeeding or plan to breastfeed. It is not known if TECHNIVIE passes into the breast milk. Person and person's doctor should decide if the person will take TECHNIVIE or breastfeed. Person should not do both. Pregnancy and Birth Control: Females must have a negative pregnancy test before starting TECHNIVIE and ribavirin, every month while on the medicine, and for 6 months after stopping them; Person or person's should not become pregnant while taking TECHNIVIE with ribavirin and for 6 months after person have stopped taking them; person and person's partner must use 2 kinds of birth control while taking TECHNIVIE and ribavirin and for 6 months after person has stopped taking them; talk to the doctor about the kind of birth control that one can use; and If person or person's partner becomes pregnant while taking TECHNIVIE and ribavirin or within 6 months after person stop taking them, tell person's doctor right away. Other warnings person should know about: Rises in liver tests have occurred when TECHNIVIE was taken in studies. Contact the doctor right away if person have symptoms like those listed below since these may mean one has a serious problem with the liver: loss of appetite (do not feel like eating); stomach ache; nausea (feeling sick in the stomach); vomiting; feeling tired or weak; yellowing of the skin and eyes; and dark urine and pale stool. It is not known if taking TECHNIVIE is safe or will work in children under 18 years of age. Person’s doctor may do blood tests before person start taking, and while person are on medicines. This is to help check if the medicines are working for patient.

AbbVie Inc. Announces Data from the Surveyor Studies of its investigational HCV Regimen, ABT-493

AbbVie Inc. announced data from the SURVEYOR studies of its investigational HCV regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, that show high rates of sustained virologic response at 12 weeks post-treatment (SVR12) in non-cirrhotic patients with chronic hepatitis C virus (HCV) infection. After 12 weeks of treatment, SVR12 rates achieved were 97-100% in genotype 1 (GT1), 96-100% in genotype 2 (GT2) and 83-94% in genotype 3 (GT3) patients. These data are being presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. Separately, in a late-breaking presentation of the SURVEYOR-I study, data show non-cirrhotic GT1 chronic HCV patients who received a shorter duration of treatment for 8 weeks with ABT-493 and ABT-530 achieved a SVR12 rate of 97%. SURVEYOR-I and SURVEYOR-II are ongoing Phase 2 clinical studies that evaluate the safety and efficacy of ABT-493 and ABT-530, with or without ribavirin (RBV), for 8 to 12 weeks. These data presented at AASLD include non-cirrhotic patients with GT1, GT2 and GT3 chronic HCV infection. Data in additional patient populations (genotypes 4-6) will be presented at future meetings.

AbbVie Announces New Data from Phase 3b TOPAZ-II Study Evaluating VIEKIRA PAK

AbbVie announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), with or without ribavirin (RBV), in adult patients with genotype 1a (GT1a) or genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection.1 Results show that 95% (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment (SVR12) after 12 or 24 weeks of treatment, a secondary endpoint for the study. These data were presented at The Liver Meeting 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. The TOPAZ-II study, a multicenter trial in the U.S., evaluates the impact of SVR12 on the progression of liver diseases over the course of five years in a diverse patient population, including genotype 1 (GT1) HCV patients with or without cirrhosis and those who were treatment-naïve or pegylated interferon (pegIFN)/RBV treatment-experienced. Patients were treated with VIEKIRA PAK, with or without RBV, according to the dosing recommendations found in the U.S. full prescribing information. VIEKIRA PAK, with or without RBV, is indicated for the treatment of patients with GT1 chronic HCV infection, including those with compensated cirrhosis (Child-Pugh A). VIEKIRA PAK is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C) due to risk of potential toxicity. TOPAZ-II is an ongoing, single arm, open-label, Phase 3b multicenter study in the U.S. evaluating the safety and efficacy of 12 or 24 weeks of treatment with VIEKIRA PAK, with or without ribavirin, in treatment-naïve or pegIFN/RBV treatment-experienced, adult patients with GT1 chronic HCV infection with or without compensated cirrhosis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4AB:GR €56.50 EUR -0.286

4AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $157.99 USD +0.36
Amgen Inc $163.52 USD -0.43
AstraZeneca PLC 4,513 GBp -7.50
Eli Lilly & Co $83.65 USD -0.09
Medtronic PLC $76.46 USD -0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation 4AB Industry Range
Price/Earnings 34.8x
Price/Sales 4.5x
Price/Book 20.2x
Price/Cash Flow 34.8x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ABBVIE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at